about
Clinical management of localized colon cancer with capecitabineCapecitabine in the management of colorectal cancerProtocol of a randomised phase III clinical trial of sequential capecitabine or 5-fluorouracil plus bevacizumab (Cape/5-FU-Bmab) to capecitabine or 5-fluorouracil plus oxaliplatin plus bevacizumab (CapeOX/mFOLFOX6-Bmab) ..Phase I study of intermittent and chronomodulated oral therapy with capecitabine in patients with advanced and/or metastatic cancer.Systemic treatment-induced gastrointestinal toxicity: incidence, clinical presentation and managementAnti-tumour efficacy of capecitabine in a genetically engineered mouse model of pancreatic cancerOral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trialsA prospective, non-randomized phase II trial of Trastuzumab and Capecitabine in patients with HER2 expressing metastasized pancreatic cancerA phase I study of sunitinib combined with modified FOLFOX6 in patients with advanced solid tumors.Neoadjuvant chronomodulated capecitabine with radiotherapy in rectal cancer: a phase II brunch regimen study.Quality-of-life findings from a randomised phase-III study of XELOX vs FOLFOX-6 in metastatic colorectal cancerA randomized two arm phase III study in patients post radical resection of liver metastases of colorectal cancer to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) vs CAPOX alone as adjuvant treatmentTargeting cancers in the gastrointestinal tract: role of capecitabineEffect of time interval between capecitabine intake and radiotherapy on local recurrence-free survival in preoperative chemoradiation for locally advanced rectal cancerA phase I study of an oral simulated FOLFOX with high dose capecitabine.A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: the AIO KRK 0110 trial/ML22011 trial.Capecitabine in gastric cancer.A phase I study of sunitinib plus capecitabine in patients with advanced solid tumorsA tolerability and pharmacokinetic study of adjuvant erlotinib and capecitabine with concurrent radiation in resected pancreatic cancerMeta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer.The effect of dihydropyrimidine dehydrogenase deficiency on outcomes with fluorouracil.Capecitabine and lapatinib uptake in surgically resected brain metastases from metastatic breast cancer patients: a prospective study.A phase I study of EKB-569 in combination with capecitabine in patients with advanced colorectal cancer.Population pharmacokinetics and concentration-effect relationships of capecitabine metabolites in colorectal cancer patients.Comparative pharmacology of oral fluoropyrimidines: a focus on pharmacokinetics, pharmacodynamics and pharmacomodulation.Capecitabine: the new generation of fluoropyrimidines in colorectal cancer.Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignanciesDifferential expression of uridine phosphorylase in tumors contributes to an improved fluoropyrimidine therapeutic activityCapecitabine: effective oral fluoropyrimidine chemotherapy.Adverse interaction between capecitabine and warfarin resulting in altered coagulation parameters and bleeding: case report and review of the literature.Modulation of oral drug bioavailability: from preclinical mechanism to therapeutic application.The use of capecitabine in daily practice: a study on adherence and patients' experiencesCapecitabine in the treatment of colorectal cancer.Capecitabine in carcinoma of the pancreas.A phase II study of fixed-dose capecitabine and assessment of predictors of toxicity in patients with advanced/metastatic colorectal cancerA phase I clinical and pharmacokinetic study of capecitabine (Xeloda) and irinotecan combination therapy (XELIRI) in patients with metastatic gastrointestinal tumours.Population pharmacokinetics of cabazitaxel in patients with advanced solid tumors.Simulations to Assess Phase II Noninferiority Trials of Different Doses of Capecitabine in Combination With Docetaxel for Metastatic Breast Cancer.Candidate mechanisms for capecitabine-related hand-foot syndrome.Phase I trial of capecitabine rapidly disintegrating tablets and concomitant radiation therapy in children with newly diagnosed brainstem gliomas and high-grade gliomas.
P2860
Q24611758-85674445-57B5-4060-895C-17F547CBE8B2Q24633039-02A86467-341C-4883-AD9C-F51D286B581AQ24658529-2825D8CC-4397-4D60-9115-976298A57B83Q25256709-381F8851-83A6-44B6-A323-A921C03AAA32Q26830695-84240538-B54E-4182-AFAD-AE21FC45C9F7Q28534413-D959A7EF-18B8-4C74-B029-4C57FD0677C5Q30913489-154AB2AF-EC90-4E7C-89D0-A4AFA753BE76Q33398693-6A16C642-E89B-4DCD-A215-AFF7F2F5085BQ33401396-494DC3AD-C4B3-41FE-9337-4F687162FD1CQ33416945-0E658BC9-A880-41D6-A41D-F52C97AE4BE3Q33620052-ED619837-937F-4E7B-AB2D-7B9009A6023CQ33715042-3FBD43F6-1D86-476C-A878-906538D0F74FQ33916021-25413931-BDF7-4CD3-B973-7F823A839195Q33919715-7B9DDF8E-44F6-4A49-B0ED-E56CD32A0D9DQ33973344-C87DE6F1-2B96-4B7A-B612-8EBD59067A84Q34001177-11C5A9A8-E7D9-4393-BA4B-C71DEE52B37DQ34236005-AE8B3341-A1D1-415E-8EED-C9BBF49A10E6Q34334959-532AB265-C2EA-45E6-9453-8962A11399D9Q34398312-28904690-0269-47A0-93DC-F2220EB65301Q34608222-AE62748D-4495-470E-BDF7-125AE8666893Q34761260-35443071-653D-4549-AAAA-851D11E2C89BQ34886764-6A37BE04-8B32-459C-899D-E4AFB86445D7Q34910416-B935EB93-115D-462D-8F32-E1D3994B7C81Q35825206-BBA32997-C4E7-441A-8E83-FD02EBB3CE2AQ35849214-E8295F88-2AB2-47B9-BEB2-F14F8F690F53Q35987726-8715ED64-ED4B-40A3-B1A2-D710C708DFE8Q36072040-1B78ACB6-80C1-44BF-A0EA-90A381D45AF0Q36097350-AA675B42-9DB9-4357-BAC5-4F2A765D3135Q36164013-9EF0ED7D-DFB8-489B-A0E4-A3A727AC33E9Q36204393-25B08D5B-FCA2-47A2-A6E5-9D81E6081A4CQ36271954-1BDD2722-5C5B-45CB-9DCD-8495505E05E8Q36358178-87787269-6517-4157-B2B8-3F819150D2C8Q36429425-629A4C6A-DBC1-4E46-A669-08FCED0E798EQ36548730-2E6A9105-0C83-4261-AA43-260954930520Q36614004-ED3547DD-151C-4575-A4D9-151F2D684DFFQ36616386-3803829E-F1FA-4CD3-907C-52B15205DA35Q36629864-77E56547-8983-4132-9630-82EA40A95ECDQ36693695-439D1525-91B0-4F1A-93C7-794D615B4EE4Q36792721-9848C030-28E4-4FA0-AFF9-11D0CE413498Q36865982-054CCEF4-3B3C-4F1F-8D93-03FFB9B81581
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Clinical pharmacokinetics of capecitabine.
@ast
Clinical pharmacokinetics of capecitabine.
@en
Clinical pharmacokinetics of capecitabine.
@nl
type
label
Clinical pharmacokinetics of capecitabine.
@ast
Clinical pharmacokinetics of capecitabine.
@en
Clinical pharmacokinetics of capecitabine.
@nl
prefLabel
Clinical pharmacokinetics of capecitabine.
@ast
Clinical pharmacokinetics of capecitabine.
@en
Clinical pharmacokinetics of capecitabine.
@nl
P2093
P1476
Clinical pharmacokinetics of capecitabine.
@en
P2093
P304
P356
10.2165/00003088-200140020-00002
P577
2001-01-01T00:00:00Z
P6179
1027359019